B&L names Valenti president, North America
ROCHESTER, N.Y. Bausch & Lomb on Friday named Peter Valenti president, North America, Vision Care, effective later this month.
“[Valenti] possesses deep leadership experience, as well as considerable eye health and general healthcare expertise,” stated Stuart Heap, corporate VP and global president, Vision Care, Bausch & Lomb. “His appointment further strengthens our existing team, which is focused on delivering innovation in the contact lens, lens care and vision accessories segments of the industry.”
Valenti was most recently VP and general manager, Surgical Devices (U.S.), for Covidien, where he led sales and marketing strategy for its $1 billion product portfolio. Prior, he spent 12 years with Johnson & Johnson, serving in a variety of U.S. and international roles across consumer, pharmaceutical and device businesses. Before his career with Johnson & Johnson, he held several brand management roles with Procter & Gamble.
He earned an MBA from the Johnson School of Management at Cornell University, and a Bachelor’s degree from the University of Connecticut. Valenti will be based in Rochester, N.Y.
Publix to open 1,000th store Feb. 5
LAKELAND, Fla. Publix will open the doors to store No. 1,000 on Feb. 5, the grocer announced Thursday. The latest addition to Publix, which will stand at 54,000 sq. ft., will include a pharmacy, bakery, deli and floral and fresh seafood departments.
“We are proud of our 79-year history, rich in providing superior customer service and delivering a high-quality selection of foods, products and services,” stated Publix president Todd Jones.
Opening day festivities will begin with a performance by the St. John’s Academy of the Arts choral group. To commemorate the milestone, Publix will grant eight local area schools $1,000 each to use toward the purchase of school supplies.
According to the company, the Florida Historical Society will be on-hand to recognize and document Publix’ milestone.
Eli Lilly agrees to settlement over alleged mispromotion of Zyprexa
WASHINGTON Drug maker Eli Lilly & Co. has agreed to pay $1.415 billion to resolve allegations that it promoted the antipsychotic drug Zyprexa for unapproved uses.
The Department of Justice announced Thursday that the Indianapolis-based company would pay a $515 million criminal fine (the largest ever in a healthcare case and the largest criminal fine ever imposed on an individual corporation) and up to $800 million in a civil settlement with the federal government and the states. It will also forfeit assets of $100 million.
The settlement will resolve criminal and civil allegations that Lilly promoted Zyprexa (olanzapine) for uses not approved by the Food and Drug Administration, including treatment of dementia in elderly people.
In a plea agreement, the company has admitted its guilt to a misdemeanor charge. It also signed a civil settlement to resolve claims that by marketing the drug for off-label uses, it caused the submission of false payment claims to federal health insurance plans such as Medicaid, TRICARE and the Federal Employee Health Benefits Program.